Polymorphism of glucagon-like peptide-1 receptor gene (rs1042044) is associated with bone mineral density in Chinese Han postmenopausal women

Suo-Chao Fu¹, Wen-Mang Xu², Ying Zhang¹, Zeng-Hui Wu¹, Hong Xia¹, Gong-Hao He³* and Qing-Shui Yin¹*

¹Department of Orthopaedics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010, China.
²Department of Pathology, Kunming General Hospital of Chengdu Military Command, Kunming 650032, China.
³Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming 650032, China.

Received 31 October, 2014; Accepted 16 February, 2015

Previous investigations indicated that glucagon-like peptide-1 (GLP-1) played important roles in bone turnover via GLP-1 receptors (GLP1Rs) in postmenopausal state. Furthermore, polymorphisms in GLP1R gene were suggested to affect the function of GLP1Rs and be associated with many diseases. However, the relationships between GLP1R polymorphisms and osteoporosis susceptibility and bone strength remain unexplored. To address this issue, a total of 458 Chinese Han postmenopausal women were included in this study. The bone mineral density (BMD) in the lumbar spine (L₂-L₄) and femoral neck was measured by dual-energy X-ray absorptiometry (DEXA). A missense mutation (rs1042044) in GLP1R was genotyped using allele specific TaqMan probes. Our data showed that genetic variants of rs1042044 were significantly associated with osteoporosis (P = 0.003) and that the C allele of rs1042044 was a protective factor against osteoporosis compared to the A allele with gene dosage-dependent manner (OR, 0.579; 95% CI, 0.366 to 0.916 for AC genotype and OR, 0.404; 95% CI, 0.238 to 0.688 for CC genotype). These findings indicate that polymorphisms in GLP1R gene may affect BMD and development of osteoporosis in Chinese Han postmenopausal women, which provide novel insight into the mechanisms of osteoporosis development and target for personal prevention and treatment of osteoporosis.

Key words: Glucagon-like peptide-1 receptor, single nucleotide polymorphism, osteoporosis, bone mineral density.

INTRODUCTION

Osteoporosis is a prevalent metabolic bone disease and an important and complex health problem in postmenopausal women (Riggs and Melton, 1986; NIH, 2001). This kind of skeletal disease is characterized by low bone mineral density (BMD) and deterioration of bone tissue, and generally believed to be a multifactorial
disorder with genetic influence accounting for up to 70% of individual variance in BMD (Jouanny et al., 1995). It was reported that, in postmenopausal state, the BMD was affected by a series of bone mass modulating factors, such as vitamin D receptor, estrogen receptor, and osteoprotegerin etc., and that polymorphisms in genes encoding these factors were significantly associated with osteoporosis risk (Horst-Sikorska et al., 2013; Gennari et al., 2005; Arko et al., 2005; Wang et al., 2013). Therefore, to define certain candidate genes responsible for regulation of bone mass and susceptibility to osteoporosis may be a beneficial approach for better understanding of the etiology and mechanisms of osteoporosis.

Recently, it was suggested that glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone, plays important roles in bone modulation via its receptors (Yamada et al., 2008). The GLP-1 receptor (GLP1R) is a cognate G-protein-coupled receptor and its activation by exogenous GLP-1 analogue, exendin-4, enhances bone strength and prevents the deterioration of trabecular microarchitecture (Ma et al., 2013). These findings suggest that GLP1R is an important bone mass modulating factor. Furthermore, some single nucleotide polymorphisms (SNPs) of GLP1R gene were found to lead to changes of expression and function of GLP1R and to be associated with development of certain diseases (Sheikh et al., 2010; Beinborn et al., 2005; Sathananthan et al., 2010). Therefore, it is rational to hypothesize that GLP1R gene might also be a candidate gene participating in bone mass turnover and development of osteoporosis.

However, to our best knowledge, no published studies regarding this issue have been performed so far. In order to prove this hypothesis, in the present study, we investigated the relationship between a common tag-SNP (rs1042044) of GLP1R and BMD in Chinese Han postmenopausal women.

MATERIALS AND METHODS

Subjects

A case-control study was performed with a total of 458 Chinese Han postmenopausal women, including 223 randomly selected primary postmenopausal osteoporosis patients (age from 48 to 79), who were enrolled from Kunming General Hospital of Chengdu Military Command between 2009 and 2013, and 235 health controls (age from 49 to 82). Menopausal status was defined as the date of last menses followed by 12 months of no menses. Individuals with current hepatic disease, renal disease, diabetes mellitus, surgical removal of both ovaries, and/or taking any drugs known to affect bone metabolism were excluded. The study protocol was designed in compliance with the principles of the Helsinki Accord, and was reviewed and approved by the local Ethical Committees. Informed consent statement was obtained from all participants after full explanation of the procedure.

Measurement of BMD

BMD was measured at the lumbar spine (L2-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA) (Lunar Expert 1313, Lunar, Madison, WI). The value of BMD was automatically calculated from bone mineral content (g) and bone area (cm²) and expressed in g/cm².

Genotyping assay

Peripheral venous blood samples (3 ml) were collected into tubes containing ethylenediaminetetraacetic acid and stored at -80°C for analysis. Genomic DNA extraction was performed using the QIAGEN DNA MicroKit® (Valencia, CA) according to the manufacturer’s instructions. The genotyping of the non-synonymous tag-SNP (rs1042044) was performed according to previous report (Sheikh et al. 2010) by TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA). Briefly, TaqMan PCR was performed in a 10 μL system containing 1× ABI TaqMan Genotyping Master Mix, TaqMan 40× probe mix, and 25 ng of DNA on an ABI StepOne™ Real-Time PCR System (Applied Biosystems) and analyzed using SDS v3.0 software (Applied Biosystems). The PCR conditions were: DNA denaturing at 95°C for 10 min, 50 cycles of replication at 95°C for 15 s, and then annealing and extension at 60.0°C for 1 min followed with final extension for 3 min. The primers used were as follows: forward 5’ CCTAGCCAGAGATGTGAGCT and reverse 5’ CAGCAGTGCGTTCCAAGTAC (chr6:39041252-39041636).

Statistical analysis

Data were analysed with SPSS 18.0 for Windows (PASW Statistics, SPSS Inc., Chicago, IL). The genotypic frequency for rs1042044 was tested for departure from Hardy–Weinberg Equilibrium (HWE). Chi-square (χ²) test was used to determine the differences of genotypic and allelic distributions between osteoporosis case and control group, and also the odds ratios (OR) with 95% confidential intervals (CIs) of osteoporosis risk. Student t test was used to determine the differences in anthropometric characteristics between case and control group. Differences in anthropometric characteristics according to genotypes were tested by one-way analysis of variance. Differences in BMD according to genotypes were analyzed by using analysis of covariance adjusting for potential confounders, that is, age, body mass index (BMI) and years since menopause.

RESULTS

Population characteristics

Descriptive statistics of both the case and control groups are shown in Table 1. There were no significant differences regarding the age (P = 0.979), BMI (P = 0.662), and years since menopause (P = 0.834) between the 2 populations. Meanwhile, the BMD values in osteoporosis case group were significantly lower compared to health controls at both lumbar spine and femoral neck (P < 0.001 for both positions).

Distributions of genotype and allele frequencies of rs1042044 between osteoporosis patients and health controls

The distributions of genotype and allele frequencies of
Table 1. Characteristics of osteoporotic and control postmenopausal women.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Case (n = 223)</th>
<th>Control (n = 235)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59.9 ± 7.2</td>
<td>59.9 ± 7.3</td>
<td>0.979</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.4 ± 2.8</td>
<td>23.3 ± 2.8</td>
<td>0.662</td>
</tr>
<tr>
<td>Years since menopause (years)</td>
<td>10.1 ± 6.9</td>
<td>10.0 ± 7.0</td>
<td>0.834</td>
</tr>
<tr>
<td>BMD (g/cm²)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>0.785 ± 0.039</td>
<td>0.973 ± 0.073</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>0.653 ± 0.071</td>
<td>0.825 ± 0.058</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 2. Frequency distribution of GLP1R rs1042044 polymorphisms and their associations with the risk of osteoporosis in postmenopausal women.

<table>
<thead>
<tr>
<th>rs1042044</th>
<th>Case</th>
<th>Control</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>69 (30.9)</td>
<td>44 (18.7)</td>
<td>1.000 [Ref]</td>
<td></td>
</tr>
<tr>
<td>AC</td>
<td>109 (48.9)</td>
<td>120 (51.1)</td>
<td>0.579 (0.366 - 0.916)</td>
<td>0.003</td>
</tr>
<tr>
<td>CC</td>
<td>45 (20.2)</td>
<td>71 (30.2)</td>
<td>0.404 (0.238 - 0.688)</td>
<td></td>
</tr>
<tr>
<td>Allele</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>247 (55.4)</td>
<td>208 (44.3)</td>
<td>1.000 [Ref]</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>199 (44.6)</td>
<td>262 (55.7)</td>
<td>0.640 (0.493 - 0.830)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

OR: odds ratio, CI: confidence interval, Ref: reference category. *P values were calculated from two-sided chi-square tests for genotype or allele distribution.

GLP1R rs1042044 in the two groups are listed in Table 2. The \( \chi^2 \) test revealed that the genotypic frequencies of both groups did not deviate from HWE (\( \chi^2 = 0.027, P = 0.870 \) for case group; and \( \chi^2 = 0.287, P = 0.592 \) for control group). In the following association analysis, we found that the genotypic frequencies in osteoporosis case group were significantly different from those of healthy control group (\( P = 0.003 \)). Furthermore, osteoporosis was much less frequently observed in the AC (OR, 0.579; 95% CI, 0.366 to 0.916) and CC (OR, 0.404; 95% CI, 0.238 to 0.688) genotypes than in the AA genotype, which exhibited an obvious gene dosage effect. Accordingly, data about the distribution of allele frequency between the two groups also showed that the C allele was significantly frequent in control group and may be a protective factor against osteoporosis (\( P = 0.001; \) OR, 0.640; 95% CI, 0.493 to 0.830).

Association of GLP1R rs1042044 genetic polymorphisms with BMD

We then combined the two groups and analyzed the differences of anthropometric characteristics according to genotypes. As shown in Table 3, no significant differences in age (\( P = 0.204 \)), BMI (\( P = 0.181 \)), or years since menopause (\( P = 0.117 \)) according to genotypes of rs1042044 were observed in the present study. However, the rs1042044 polymorphism was found to be still significantly associated with BMD at both lumbar spine and femoral neck (\( P < 0.001 \)) even after adjustment for the possible confounding factors (age, BMI, and years since menopause). Interestingly, these data also exhibited a gene dosage effect that the number of the C allele in the genotypes was positively correlated with the BMD values (Table 3).

DISCUSSION

GLP-1, which induces a variety of physiological effects by activating GLP1R, is mainly produced by L-cells primarily localized in the ileal/colonic mucosa and is hence considered as an important gastrointestinal hormones (Drucker, 1998; Kieffer and Habener, 1999). However, the role of GLP1R gene in the pathology of osteoporosis is unclear and need to be investigated. It was recently reported that the entero-bone endocrine axis was proposed as a mediator of bone turnover (Isales and Hamrick, 2008). Therefore, the association between GLP1R and BMD and osteoporosis seems to be quite plausible with regard that growing evidence indicated that osteoporosis is a multifactorial and polygenic disease (Zhao et al., 2005; Lee et al., 2014). In the present study, we assessed the effects of rs1042044 polymorphism in GLP1R gene on BMD values and osteoporosis risk in...
The authors have not declared any conflict of interest.
like peptide-1; GLP1R, glucagon-like peptide-1 receptor; HWE, Hardy–Weinberg Equilibrium; ORs, odds ratios; SNP, single nucleotide polymorphism.

REFERENCES


